☆ 4.6 Article

Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy

HISTOPATHOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Christina Yau et al.

Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.

LANCET ONCOLOGY (2022)

Add to Collection

Article Pathology

Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer

Ricardo G. Pastorello et al.

Summary: Among breast cancer patients treated with neoadjuvant chemotherapy who do not achieve a pathologic complete response, the pattern of residual disease correlates with tumor subtype, histologic grade, and tumor size. Understanding these relationships may be valuable in guiding post-chemotherapy surgical management.

MODERN PATHOLOGY (2021)

Add to Collection

Article Oncology

Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy

Olga Kantor et al.

Summary: This study compared the performance of different staging systems in breast cancer patients after neoadjuvant chemotherapy and found that AJCC pathologic prognostic staging and RCB had better discrimination for disease-free survival and overall survival compared to the Neo-Bioscore. Results validate the ability of these staging systems to stratify survival outcomes in NAC patients, with best discrimination achieved using AJCC pathologic prognostic stage or RCB.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Laura M. Spring et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medical Laboratory Technology

Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens A Survey of Canadian Pathologists and Pathology Assistants

Rachel Han et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

The importance of histological assessment after neoadjuvant therapy and the need for standardisation

K. Naidoo et al.

CLINICAL RADIOLOGY (2018)

Add to Collection

Article Oncology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Surgery

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System Review of the Supporting Evidence

Anna Weiss et al.

SURGICAL CLINICS OF NORTH AMERICA (2018)

Add to Collection

Article Oncology

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

W. Fraser Symmans et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Jeffrey I. Campbell et al.

BREAST CANCER RESEARCH AND TREATMENT (2017)

Add to Collection

Article Oncology

Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual

Armando E. Giuliano et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2017)

Add to Collection

Review Oncology

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

V. Bossuyt et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy

W. Fraser Symmans et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.